Citius Pharmaceuticals (NASDAQ:CTXR) has exercised its previously announced option agreement, andannounced an exclusive agreement with Novellus Therapeutics to license iPSC-derived mesenchymal stem cells (iMSCs).

The company has created a new subsidiary, NoveCite, that will focus on development and commercialization of NoveCite mesenchymal stem cells (NC-iMSCs) for the treatment of acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.

See original here:

Citius Pharma inks license pact with Novellus for stem cell therapy in respiratory distress - Seeking Alpha

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh